Literature DB >> 6785799

A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness.

T Okuma, K Inanaga, S Otsuki, K Sarai, R Takahashi, H Hazama, A Mori, S Watanabe.   

Abstract

A preliminary double-blind controlled study on the prophylactic effect of carbamazepine on recurrent manic-depressive psychotics was conducted with 22 patients using an inert placebo in ten subjects as a control drug. Carbamazepine in the dosage of 200-600 mg was administered for 1 year. Among the 22 carbamazepine subjects, carbamazepine was found to be effective in 60% of the cases and inert placebo in 22.2% (U-test, P less than 0.10). It is suggested that carbamazepine is a useful drug for the prophylaxis of manic-depressive illness.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6785799     DOI: 10.1007/BF00431111

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  2 in total

1.  Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study.

Authors:  T Okuma; K Inanaga; S Otsuki; K Sarai; R Takahashi; H Hazama; A Mori; M Watanabe
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

2.  Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report.

Authors:  T Okuma; A Kishimoto; K Inoue; H Matsumoto; A Ogura
Journal:  Folia Psychiatr Neurol Jpn       Date:  1973
  2 in total
  17 in total

Review 1.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 2.  The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 2: Review, Grading of the Evidence, and a Precise Algorithm.

Authors:  Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller
Journal:  Int J Neuropsychopharmacol       Date:  2017-02-01       Impact factor: 5.176

Review 3.  Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry.

Authors:  Konstantinos N Fountoulakis; Siegfried Kasper; Ole Andreassen; Pierre Blier; Ahmed Okasha; Emanuel Severus; Marcio Versiani; Rajiv Tandon; Hans-Jürgen Möller; Eduard Vieta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06       Impact factor: 5.270

Review 4.  Mitochondrial dysfunction as the molecular basis of bipolar disorder: therapeutic implications.

Authors:  Tadafumi Kato
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

5.  The effects of carbamazepine on two animal models of depression.

Authors:  H M Barros; J R Leite
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 6.  Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis.

Authors:  Eduard Vieta; Marc Valentí
Journal:  CNS Drugs       Date:  2013-07       Impact factor: 5.749

Review 7.  The manic syndrome: factors which may predict a patient's response to lithium, carbamazepine and valproate.

Authors:  S C Dilsaver; A C Swann; A M Shoaib; T C Bowers
Journal:  J Psychiatry Neurosci       Date:  1993-03       Impact factor: 6.186

Review 8.  The use of carbamazepine in the treatment of schizophrenic and schizoaffective psychoses: a review.

Authors:  C Simhandl; K Meszaros
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

9.  Anticonvulsant Use in the Treatment of Bipolar Disorder: A Primer for Primary Care Physicians.

Authors:  Raphael J. Leo; Rajesh Narendran
Journal:  Prim Care Companion J Clin Psychiatry       Date:  1999-06

10.  Effects of acute or chronic carbamazepine on experimentally-induced conflict in the rat.

Authors:  R N Almeida; J R Leite
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.